# Sable Bio

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/sable-bio

- Industry: Software
- Headquarters: London, UK
- Website: www.sablebio.com
- Total disclosed funding: $5.9M
- Latest round: Seed (Sep 8, 2025)
- Investors on record: 3

## About

Based in London, UK, and founded in 2023, Sable Bio Limited, also known as Sable, operates as an AI-enabled drug discovery company. The company was founded by Josh Almond-Thynne and Alex de Giorgio. In February 2026, Sable Bio Limited raised GBP 2.7 million in seed funding.

Sable provides B2B (business-to-business) software solutions for biotech and pharma companies. The company’s product includes a drug discovery platform that uses artificial intelligence and large language models to analyze structured and unstructured data sources from multiple sources, including clinical trials, for personalized drug predictions and safety assessments.

The company plans to use the funds raised in February 2024 to enhance its fundamental technology infrastructure and its robust and extensive data capabilities.

## Funding rounds

- Seed, Sep 8, 2025, $5.9M — MMC Ventures, Seedcamp, Episode 1 Ventures

## Investors

- MMC Ventures (https://capitalatlas.ai/funds/mmc-ventures) — Seed
- Seedcamp (https://capitalatlas.ai/funds/seedcamp) — Seed
- Episode 1 Ventures (https://capitalatlas.ai/funds/episode-1-ventures) — Seed